Bothersome hot flashes following relugolix and stereotactic body radiotherapy for localized prostate cancer.

• DOI: 10.1200/jco.2025.43.16_suppl.e17087
• Publication Date: 2025-05-28T16:28:13Z
• Authors: Sukhjeevan Nijhar; Sarthak Shah; Srinivas Sowmiyan...; Omar Anwar; Abigail Pepin; Malika Danner; Alan Zwart; Deepak Kumar; Paul Denis Leger; Nancy Ann Dawson; Simeng Suy; Sean P. Collins

e17087 Background: Androgen deprivation therapy (ADT) has been shown to improve cancer control when combined with radiation therapy. Relugolix is an oral GnRH receptor antagonist that achieves rapid profound testosterone suppression. ADT cause several hormonally related symptoms resolve recovery. Hot flashes are particularly bothersome. This prospective study sought evaluate the timeline of hot following initiation a short course and stereotactic body radiotherapy (SBRT) for unfavorable localized prostate cancer. Methods: Institutional IRB (IRB #12-1775) approval was obtained retrospective review prospectively collected data. Patients were treated at Georgetown between per institutional protocol. self-reported via question 13a Expanded Prostate Index Composite (EPIC)-26 prior initiation, first day SBRT, each follow-up (1-, 3-, 6-, 9-, 12-months). The responses grouped into three relevant categories (no problem, very small-small problem moderate big problem). Scores transformed 0-100 scale higher scores reflecting less bother. All patients robotic SBRT (Accuray). Total Testosterone levels measured follow-up. Items evaluated statistical significance (paired t-test, p <0.05) clinical (minimally important difference (MID); 0.5 standard deviation from baseline). Results: 89 (20 intermediate risk, 63 high 6 recurrent) median age 71.5 years (range 49-89 years) who (35-36.35 Gy) relugolix average length 6.25 months 3-29 months) January 2021 September 2023 single institution included in this study. Thirty seven percent non-white 24% obese. initiated 3 (range, 0-11) completed 2 0-36 post-SBRT. Prior 1.3% men reported problem. That proportion peaked 1-month post-SBRT (46.2%) before returning baseline 9 (0%) cumulative incidence 57%. EPIC-26 flash score 98.7 declined 49.0 returned by 9-months These differences statistically (P < 0.01) clinically significant (MCID = 98.8 +/- 4.45). recovery (> 230 ng/dL) occurred 97% 12 Conclusions: Bothersome occur greater than 50% SBRT. Resolution occurs majority post resolution mirrored Reassurance temporary nature may reduce patient anxiety limit associated